ALX Oncology Announces Upcoming Investor Conference Participation
ALX Oncology Holdings Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment, is excited to share details of its upcoming participation in significant investor conferences. The company's leadership team is set to present at the prestigious Jefferies Global Healthcare Conference and the Piper Sandler 37th Annual Global Healthcare Conference.
Jefferies Global Healthcare Conference Details
The Jefferies Global Healthcare Conference will be held in London. During this conference, ALX Oncology will host a fireside chat to discuss the latest advancements in their therapeutic pipeline. This event provides a vital platform for industry leaders to engage in conversations about the future of cancer treatment options.
Event Schedule
The fireside chat is scheduled for Wednesday, November 19, 2025, at 11:30 AM GMT / 6:30 AM EST. As part of this event, participants will also have access to a detailed webcast, which will be available for viewing online.
Piper Sandler 37th Annual Global Healthcare Conference
Following the Jefferies conference, ALX Oncology will continue its outreach efforts at the Piper Sandler Global Healthcare Conference located in New York. This platform is essential for showcasing ALX Oncology's continued commitment to advancing cancer therapies.
Event Schedule
The Piper Sandler fireside chat is taking place on Wednesday, December 3, 2025, at 9:30 AM EST. ALX Oncology encourages attendees and interested parties to tune in through the webcast made available during the presentation.
Accessing Webcasts of Both Conferences
Webcasts for both the Jefferies and Piper Sandler fireside chats can be accessed directly through the Investors section of ALX Oncology's official website. These recordings will be available to the public and will be archived for a period of 90 days following the events.
About ALX Oncology
ALX Oncology is dedicated to pioneering advancements in cancer therapies designed to extend the lives of patients. Their lead therapeutic candidate, evorpacept, showcases remarkable potential as a cornerstone in the immuno-oncology segment. Currently, evorpacept is undergoing multiple clinical trials aimed at various cancer indications. Additionally, ALX Oncology is advancing a second pipeline candidate, ALX2004, which recently entered Phase 1 trials. ALX2004 represents a novel EGFR-targeted antibody-drug conjugate aimed at enhancing treatment efficacy.
For more information about ALX Oncology and its groundbreaking initiatives in oncology, visit their official website.
Investor Relations Contact
Elhan Webb, CFA
IR Consultant
Email: ewebb@alxoncology.com
Media Contact
Audra Friis
Sam Brown Healthcare Communications
Email: audrafriis@sambrown.com
Phone: (917) 519-9577
Frequently Asked Questions
What is ALX Oncology's primary focus?
ALX Oncology focuses on developing therapies aimed at treating cancer and improving patient survival.
When is ALX Oncology participating in the Jefferies Global Healthcare Conference?
They will participate on November 19, 2025.
What does ALX Oncology's lead candidate, evorpacept, target?
Evorpacept is designed to be a cornerstone therapy in immuno-oncology, targeting cancer effectively.
Could I access the webcasts for the investor conferences?
Yes, the webcasts will be available on the Investors section of ALX Oncology's website.
How can I contact ALX Oncology for investor relations?
You can contact Elhan Webb, CFA, at ewebb@alxoncology.com.